PTC Therapeutics (PTCT) Financials

$71.02 +0.71 (+1.01%)

Closing price 04:00 PM Eastern

Extended Trading

$68.61 -2.41 (-3.39%)

As of 08:00 PM Eastern

Annual Income Statements for PTC Therapeutics

This table shows PTC Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-170	-142	-79	-128	-252	-438	-524	-559	-627	-363	683
Consolidated Net Income / (Loss)	-170	-142	-79	-128	-252	-438	-524	-559	-627	-363	683
Net Income / (Loss) Continuing Operations	-170	-142	-79	-128	-252	-438	-524	-559	-627	-363	683
Total Pre-Tax Income	-170	-142	-78	-128	-240	-403	-518	-587	-696	-363	697
Total Operating Income	-167	-132	-64	-116	-241	-432	-374	-447	-440	-303	867
Total Gross Profit	37	83	190	252	295	362	506	654	938	749	1,731
Total Revenue	37	83	194	265	307	381	539	699	938	807	1,731
Operating Revenue	37	83	194	265	307	381	539	699	938	807	1,731
Total Cost of Revenue	0.00	0.00	4.58	13	12	19	32	45	0.00	57	0.00
Total Operating Expenses	204	215	254	368	536	794	881	1,102	1,377	1,052	864
Selling, General & Admin Expense	82	97	121	154	203	245	286	326	333	301	347
Marketing Expense	-	0.00	-	-	-	-	-	-	65	-	47
Research & Development Expense	122	118	117	172	257	478	541	651	667	534	455
Amortization Expense	0.00	0.00	15	23	28	37	55	117	223	61	25
Other Operating Expenses / (Income)	-	0.00	0.00	19	48	34	-0.50	-26	-128	-4.48	-0.80
Impairment Charge	-	-	-	-	-	0.00	0.00	33	218	160	-9.63
Total Other Income / (Expense), net	-2.83	-9.48	-13	-12	1.23	29	-144	-140	-257	-61	-170
Interest Expense	-	-	-	-	-	-	0.00	0.00	138	0.00	0.00
Interest & Investment Income	-2.37	-8.28	-12	-13	-12	-56	-86	-91	-129	-67	-152
Other Income / (Expense), net	-0.47	-1.21	-1.28	0.13	14	85	-58	-49	10	6.54	-18
Income Tax Expense	0.49	0.57	1.34	-0.03	12	35	5.56	-28	-70	0.18	14
Basic Earnings per Share	($5.07)	($4.17)	($2.02)	($2.75)	($4.27)	($6.64)	($7.43)	($7.79)	($8.37)	($4.73)	$8.58
Weighted Average Basic Shares Outstanding	33.63M	34.04M	39.18M	46.58M	58.86M	66.03M	70.47M	71.73M	74.84M	76.85M	79.53M
Diluted Earnings per Share	($5.07)	($4.17)	($2.02)	($2.75)	($4.27)	($6.64)	($7.43)	($7.79)	($8.37)	($4.73)	$7.78
Weighted Average Diluted Shares Outstanding	33.63M	34.04M	39.18M	46.58M	58.86M	66.03M	70.47M	71.73M	74.84M	76.85M	88.31M
Weighted Average Basic & Diluted Shares Outstanding	33.63M	34.04M	39.18M	46.58M	58.86M	66.03M	71.36M	73.82M	76.61M	78.87M	82.77M

This table shows PTC Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-133	-156	-92	-99	-107	-66	867	-65	16	-135	-2.81
Consolidated Net Income / (Loss)	-133	-156	-92	-99	-107	-66	867	-65	16	-135	-2.81
Net Income / (Loss) Continuing Operations	-133	-156	-92	-99	-107	-66	867	-65	16	-135	-2.81
Total Pre-Tax Income	-167	-157	-85	-86	-98	-95	930	-71	-23	-139	-2.46
Total Operating Income	-118	5.82	-45	-40	-55	-162	970	-35	3.02	-71	45
Total Gross Profit	187	343	195	171	197	156	1,176	167	211	189	245
Total Revenue	197	307	210	187	197	213	1,176	179	211	165	273
Operating Revenue	197	307	210	187	197	213	1,176	179	211	165	273
Total Cost of Revenue	9.49	-36	15	16	0.00	57	0.00	11	0.00	-24	28
Operating Cost of Revenue	9.49	-	15	16	-	-	-	11	-	-	28
Total Operating Expenses	305	338	241	211	251	318	206	202	208	260	200
Selling, General & Admin Expense	81	76	73	70	73	85	81	85	84	97	86
Research & Development Expense	164	121	116	132	161	125	109	113	100	133	101
Amortization Expense	59	77	52	2.87	3.04	3.31	3.80	4.06	7.53	9.35	12
Other Operating Expenses / (Income)	1.50	-2.70	-0.10	5.10	0.70	-10	-0.80	0.00	0.00	-	0.00
Impairment Charge	0.00	-	0.00	1.76	1.84	-	0.08	0.10	0.47	-10	0.93
Total Other Income / (Expense), net	-48	-163	-39	-46	-43	68	-40	-36	-26	-68	-47
Interest & Investment Income	-28	-44	-41	-43	-42	59	-34	-30	-33	-55	-49
Other Income / (Expense), net	-20	19	1.59	-2.03	-1.87	8.85	-6.31	-5.74	6.50	-13	1.61
Income Tax Expense	-34	-1.26	6.88	13	8.66	-29	63	-6.20	-39	-4.12	0.35
Basic Earnings per Share	($1.76)	($2.07)	($1.20)	($1.29)	($1.39)	($0.85)	$11.09	($0.83)	$0.20	($1.88)	($0.03)
Weighted Average Basic Shares Outstanding	75.38M	74.84M	76.50M	76.73M	76.93M	76.85M	78.12M	78.15M	78.47M	79.53M	82.52M
Diluted Earnings per Share	($1.76)	($2.07)	($1.20)	($1.29)	($1.39)	($0.85)	$10.04	($0.83)	$0.20	($1.63)	($0.03)
Weighted Average Diluted Shares Outstanding	75.38M	74.84M	76.50M	76.73M	76.93M	76.85M	86.39M	78.15M	87.12M	88.31M	82.52M
Weighted Average Basic & Diluted Shares Outstanding	75.46M	76.61M	76.70M	76.92M	77.13M	78.87M	79.26M	79.44M	80.29M	82.77M	8.29M

This table details how cash moves in and out of PTC Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	8.27	0.30	53	58	126	-79	-19	99	314	185	203
Net Cash From Operating Activities	-124	-104	-10	-28	-99	-194	-251	-357	-158	-108	711
Net Cash From Continuing Operating Activities	-124	-104	-10	-28	-99	-194	-251	-357	-158	-108	711
Net Income / (Loss) Continuing Operations	-170	-142	-79	-128	-252	-438	-524	-559	-627	-363	683
Consolidated Net Income / (Loss)	-170	-142	-79	-128	-252	-438	-524	-559	-627	-363	683
Depreciation Expense	2.88	3.29	18	26	32	43	64	129	237	76	39
Amortization Expense	2.59	2.19	0.97	0.09	-1.23	43	7.15	3.61	-0.33	-11	-17
Non-Cash Adjustments To Reconcile Net Income	36	42	37	41	44	92	225	225	411	151	60
Changes in Operating Assets and Liabilities, net	4.70	-9.16	13	34	78	66	-24	-155	-179	40	-53
Net Cash From Investing Activities	-21	104	13	-43	-387	-562	219	290	-177	44	-862
Net Cash From Continuing Investing Activities	-21	104	13	-43	-387	-562	219	290	-177	44	-862
Purchase of Property, Plant & Equipment	-2.72	-1.78	-3.10	-7.10	-14	-18	-28	-32	-28	-6.50	-8.86
Acquisitions	0.00	0.00	-77	-57	-36	-38	-57	-120	-92	-68	-291
Purchase of Investments	-224	-85	-81	-69	-494	-1,440	-543	-76	-212	-667	-1,417
Sale of Property, Plant & Equipment	-	-	-	-	-	-	-	0.00	0.00	28	0.07
Sale and/or Maturity of Investments	206	192	175	90	156	944	848	518	156	598	855
Other Investing Activities, net	-	-	-	-	0.00	-10	-	0.00	0.00	160	0.00
Net Cash From Financing Activities	154	0.97	44	132	613	669	21	168	646	256	331
Net Cash From Continuing Financing Activities	154	0.97	44	132	613	669	21	168	646	256	331
Repayment of Debt	-	0.00	-0.43	0.00	-12	-29	0.00	-161	-382	0.00	0.00
Issuance of Common Equity	0.00	0.00	2.47	121	327	33	5.79	56	5.95	5.20	5.94
Other Financing Activities, net	4.06	0.97	2.18	11	18	664	15	-27	1,023	251	325
Effect of Exchange Rate Changes	-0.64	-1.58	6.20	-3.61	-1.30	7.69	-7.82	-2.77	3.11	-7.33	23
Cash Interest Paid	0.00	4.51	6.27	7.77	7.69	9.80	9.59	18	36	5.82	5.70
Cash Income Taxes Paid	0.11	0.94	1.10	1.58	2.11	26	7.71	4.92	14	18	37

This table details how cash moves in and out of PTC Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	-43	429	-46	104	-129	256	701	-463	-347	312	-148
Net Cash From Operating Activities	-15	-100	71	-71	-77	-30	870	-58	-66	-34	-59
Net Cash From Continuing Operating Activities	-15	-100	71	-71	-77	-30	870	-58	-66	-34	-59
Net Income / (Loss) Continuing Operations	-133	-156	-92	-99	-107	-66	867	-65	16	-135	-2.81
Consolidated Net Income / (Loss)	-133	-156	-92	-99	-107	-66	867	-65	16	-135	-2.81
Depreciation Expense	62	81	55	7.02	6.49	6.76	7.22	7.58	11	13	15
Amortization Expense	0.57	-1.81	-3.40	-3.00	-2.65	-2.28	-2.01	-4.25	-5.80	-4.74	-3.81
Non-Cash Adjustments To Reconcile Net Income	47	58	45	30	15	61	41	20	-2.63	1.41	43
Changes in Operating Assets and Liabilities, net	9.00	-81	65	-6.08	11	-30	-43	-17	-85	91	-111
Net Cash From Investing Activities	-30	-94	-115	-66	-43	268	-184	-422	-290	34	-94
Net Cash From Continuing Investing Activities	-30	-94	-115	-66	-43	268	-184	-422	-290	34	-94
Purchase of Property, Plant & Equipment	-6.36	-5.57	-9.59	7.38	-0.52	-3.77	-1.72	-1.32	-3.45	-2.37	-1.20
Acquisitions	-23	-23	-55	-	-10	-2.73	-0.81	-2.68	-253	-35	-0.16
Purchase of Investments	-8.22	-186	-113	-196	-217	-141	-328	-537	-234	-319	-479
Sale of Property, Plant & Equipment	-	-	0.00	-	0.02	-	0.07	-	-	-	0.00
Sale and/or Maturity of Investments	7.83	120	63	94	175	265	146	119	200	391	386
Net Cash From Financing Activities	3.36	620	0.54	246	-18	26	9.41	3.96	15	303	6.40
Net Cash From Continuing Financing Activities	3.36	620	0.54	246	-18	26	9.41	3.96	15	303	6.40
Other Financing Activities, net	3.45	1,000	0.54	245	-18	23	9.41	1.13	15	299	6.40
Effect of Exchange Rate Changes	-2.33	3.10	-2.03	-5.19	8.54	-8.65	5.39	14	-6.06	9.80	-1.52
Cash Interest Paid	12	2.11	3.67	-	2.16	-	2.16	-	3.55	-	2.16

This table presents PTC Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	365	269	392	1,119	1,624	2,208	1,938	1,706	1,896	1,705	2,899
Total Current Assets	356	261	249	321	779	1,232	954	694	1,219	1,366	2,274
Cash & Equivalents	58	58	112	-	288	209	190	280	594	780	985
Short-Term Investments	281	173	79	58	399	895	584	131	283	360	961
Accounts Receivable	11	25	40	68	56	70	110	156	161	159	182
Inventories, net	-	0.00	11	16	19	19	16	22	31	23	80
Prepaid Expenses	5.93	4.69	6.67	9.25	18	39	55	106	150	44	67
Plant, Property, & Equipment, net	8.97	7.43	8.38	13	22	34	53	73	87	61	55
Total Noncurrent Assets	0.36	0.63	134	786	823	943	931	939	590	279	569
Goodwill	-	-	0.00	82	82	82	82	82	82	82	82
Intangible Assets	-	0.00	133	701	711	715	725	706	379	119	389
Other Noncurrent Operating Assets	0.36	0.63	1.22	2.30	30	145	124	151	128	77	98
Total Liabilities & Shareholders' Equity	365	269	392	1,119	1,624	2,208	1,938	1,706	1,896	1,705	2,899
Total Liabilities	139	150	235	768	1,029	1,726	1,937	2,053	2,714	2,803	3,104
Total Current Liabilities	45	50	82	167	236	277	509	406	603	581	968
Short-Term Debt	-	-	0.00	12	20	0.00	150	-	-	0.00	287
Accounts Payable	45	49	76	128	159	242	289	320	392	304	381
Current Deferred Revenue	0.14	0.00	3.94	3.72	8.24	4.15	0.00	1.35	0.80	5.51	2.04
Other Current Liabilities	0.00	0.87	1.67	23	48	31	71	85	210	271	298
Total Noncurrent Liabilities	94	100	153	602	794	1,449	1,427	1,646	2,111	2,222	2,136
Other Noncurrent Operating Liabilities	2.05	0.34	0.24	329	365	1,003	1,008	972	1,771	1,937	2,136
Total Equity & Noncontrolling Interests	226	120	156	351	594	482	1.44	-347	-819	-1,098	-205
Total Preferred & Common Equity	226	120	156	351	594	482	1.44	-347	-819	-1,098	-205
Total Common Equity	226	120	156	351	594	482	1.44	-347	-819	-1,098	-205
Common Stock	820	856	967	1,288	1,795	2,172	2,124	2,305	2,466	2,575	2,748
Retained Earnings	-593	-735	-814	-939	-1,190	-1,629	-2,098	-2,657	-3,284	-3,647	-2,964
Accumulated Other Comprehensive Income / (Loss)	-1.20	-1.49	3.97	1.46	-11	-61	-24	4.80	-1.29	-26	11

This table presents PTC Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	1,576	1,609	1,338	1,260	1,790	1,916	1,842	2,655	2,634	2,644	2,869
Total Current Assets	517	613	590	540	1,169	1,358	1,282	2,316	2,273	2,008	2,254
Cash & Equivalents	104	167	208	165	548	655	526	1,480	1,017	673	834
Short-Term Investments	184	119	130	130	336	439	487	547	972	1,015	1,058
Accounts Receivable	124	202	178	166	198	187	200	210	196	203	220
Inventories, net	15	27	32	36	30	32	36	22	34	53	76
Prepaid Expenses	90	99	42	44	56	46	33	57	54	64	66
Plant, Property, & Equipment, net	67	79	82	85	93	66	63	59	57	57	53
Total Noncurrent Assets	992	916	666	634	528	492	498	280	304	579	562
Goodwill	82	82	82	82	82	82	82	82	82	82	82
Intangible Assets	750	686	452	423	330	330	330	118	144	396	381
Other Noncurrent Operating Assets	160	147	132	129	116	80	85	79	78	100	99
Total Liabilities & Shareholders' Equity	1,576	1,609	1,338	1,260	1,790	1,916	1,842	2,655	2,634	2,644	2,869
Total Liabilities	1,803	2,066	1,917	1,931	2,684	2,897	2,897	2,841	2,841	2,799	3,050
Total Current Liabilities	420	442	476	492	575	610	611	595	628	866	924
Short-Term Debt	0.00	-	-	-	-	-	-	-	-	286	287
Accounts Payable	329	332	359	371	331	339	336	318	339	303	313
Current Deferred Revenue	-	0.21	0.00	1.22	0.00	0.00	0.00	13	9.76	1.69	0.50
Other Current Liabilities	91	109	118	120	244	271	274	265	279	275	323
Total Noncurrent Liabilities	1,383	1,625	1,441	1,439	2,109	2,287	2,286	2,246	2,213	1,933	2,126
Other Noncurrent Operating Liabilities	963	950	816	813	1,769	1,946	1,945	1,960	1,927	1,933	2,126
Total Equity & Noncontrolling Interests	-227	-458	-579	-671	-894	-980	-1,054	-186	-207	-156	-180
Total Preferred & Common Equity	-227	-458	-579	-671	-894	-980	-1,054	-186	-207	-156	-180
Total Common Equity	-227	-458	-579	-671	-894	-980	-1,054	-186	-207	-156	-180
Common Stock	2,223	2,340	2,417	2,447	2,487	2,511	2,531	2,609	2,631	2,668	2,778
Retained Earnings	-2,486	-2,796	-2,995	-3,128	-3,375	-3,474	-3,581	-2,780	-2,845	-2,829	-2,967
Accumulated Other Comprehensive Income / (Loss)	36	-1.59	-1.43	9.61	-5.56	-16	-4.34	-14	7.36	5.93	8.47

This table displays calculated financial ratios and metrics derived from PTC Therapeutics' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	45.64%	124.95%	135.04%	36.19%	15.96%	24.04%	41.45%	29.75%	34.20%	-13.97%	114.51%
EBITDA Growth	-69.27%	21.18%	63.28%	-90.49%	-119.83%	-32.47%	-38.71%	-0.87%	46.97%	-19.98%	475.87%
EBIT Growth	-68.22%	20.48%	50.80%	-76.23%	-96.82%	-52.39%	-24.74%	-14.87%	13.54%	31.06%	386.75%
NOPAT Growth	-68.12%	20.98%	51.32%	-79.94%	-108.46%	-79.04%	13.28%	-19.49%	1.77%	31.16%	501.11%
Net Income Growth	-81.80%	16.63%	44.41%	-62.13%	-96.42%	-74.17%	-19.57%	-6.70%	-12.09%	42.02%	287.90%
EPS Growth	-70.71%	17.75%	51.56%	-36.14%	-55.27%	-55.50%	-11.90%	-4.85%	-7.45%	43.49%	264.48%
Operating Cash Flow Growth	-117.09%	16.71%	90.28%	-174.68%	-256.86%	-96.75%	-29.51%	-41.91%	55.58%	32.02%	760.42%
Free Cash Flow Firm Growth	-92.00%	11.57%	-69.63%	-46.11%	53.73%	302.93%	-200.96%	-99.73%	296.18%	-64.08%	131.05%
Invested Capital Growth	-25.65%	34.20%	894.42%	150.68%	-19.75%	-241.01%	-8.95%	45.35%	-658.36%	-38.36%	4.52%
Revenue Q/Q Growth	0.21%	17.73%	37.33%	-14.61%	26.19%	58.68%	-11.80%	0.31%	17.50%	-10.42%	-2.73%
EBITDA Q/Q Growth	-10.44%	15.25%	42.58%	-102.86%	-10.65%	41.09%	-164.54%	-9.06%	54.31%	-1,201.73%	9.19%
EBIT Q/Q Growth	-10.87%	15.18%	31.28%	-66.22%	-10.21%	33.80%	-115.24%	-10.97%	30.67%	-151.50%	8.94%
NOPAT Q/Q Growth	-10.57%	14.95%	32.14%	-63.68%	-15.98%	23.03%	-60.50%	-34.84%	31.93%	-125.19%	7.93%
Net Income Q/Q Growth	-16.13%	14.53%	26.21%	-52.36%	-16.12%	26.27%	-73.36%	-5.20%	2.35%	19.84%	-9.19%
EPS Q/Q Growth	-21.88%	14.90%	30.10%	-67.68%	-3.64%	2.21%	-15.73%	-4.28%	3.24%	20.50%	-9.11%
Operating Cash Flow Q/Q Growth	-21.90%	14.11%	77.47%	-414.46%	4.77%	-38.71%	-1.81%	-37.42%	29.31%	39.49%	-0.60%
Free Cash Flow Firm Q/Q Growth	-7.60%	6.22%	14.45%	-13.59%	9.34%	14.51%	-47.86%	-40.97%	414.05%	-74.58%	35.51%
Invested Capital Q/Q Growth	-129.79%	-19.52%	-7.94%	-3.98%	-17.34%	4.45%	-2.54%	20.00%	-259.56%	-9.52%	-19.70%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	97.65%	95.21%	96.05%	95.03%	94.00%	93.61%	100.00%	92.89%	100.00%
EBITDA Margin	-440.98%	-154.51%	-24.14%	-33.76%	-64.01%	-68.36%	-67.03%	-52.11%	-20.59%	-28.72%	50.32%
Operating Margin	-454.58%	-159.67%	-33.07%	-43.70%	-78.56%	-113.39%	-69.52%	-64.03%	-46.86%	-37.50%	50.09%
EBIT Margin	-455.84%	-161.13%	-33.73%	-43.65%	-74.09%	-91.02%	-80.27%	-71.07%	-45.78%	-36.69%	49.05%
Profit (Net Income) Margin	-463.60%	-171.83%	-40.64%	-48.38%	-81.95%	-115.07%	-97.27%	-80.00%	-66.81%	-45.03%	39.44%
Tax Burden Percent	100.29%	100.40%	101.72%	99.98%	104.86%	108.74%	101.07%	95.15%	90.02%	100.05%	97.99%
Interest Burden Percent	101.41%	106.21%	118.44%	110.86%	105.49%	116.26%	119.90%	118.30%	162.12%	122.66%	82.07%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	2.01%
Return on Invested Capital (ROIC)	0.00%	0.00%	-93.47%	-41.92%	-67.83%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	-55.64%	36.03%	-30.82%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	36.23%	-8.58%	14.58%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-65.00%	-82.24%	-57.24%	-50.51%	-53.24%	-81.42%	-216.75%	323.46%	107.51%	37.91%	-104.75%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	-153.44%	-127.86%	-45.92%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-47.99%	-42.00%	-19.84%	-15.30%	-16.58%	-18.09%	-20.85%	-27.26%	-23.85%	-16.44%	36.88%
Return on Assets (ROA)	-48.80%	-44.79%	-23.90%	-16.95%	-18.34%	-22.87%	-25.27%	-30.68%	-34.80%	-20.18%	29.66%
Return on Common Equity (ROCE)	-65.00%	-82.24%	-57.24%	-50.51%	-53.24%	-81.42%	-216.75%	323.46%	107.51%	37.91%	-104.75%
Return on Equity Simple (ROE_SIMPLE)	-75.42%	-118.84%	-50.50%	-36.52%	-42.33%	-90.91%	0.00%	161.06%	76.55%	33.08%	0.00%
Net Operating Profit after Tax (NOPAT)	-117	-92	-45	-81	-169	-302	-262	-313	-308	-212	850
NOPAT Margin	-318.20%	-111.77%	-23.15%	-30.59%	-54.99%	-79.38%	-48.67%	-44.82%	-32.80%	-26.25%	49.09%
Net Nonoperating Expense Percent (NNEP)	-19.01%	-26.11%	-37.83%	-77.95%	-37.01%	-23.29%	-46.07%	-271.75%	-147.83%	-20.94%	-13.28%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-139.42%	57.58%	26.06%	1,044.72%
Cost of Revenue to Revenue	0.00%	0.00%	2.35%	4.79%	3.95%	4.97%	6.00%	6.39%	0.00%	7.11%	0.00%
SG&A Expenses to Revenue	223.25%	117.44%	62.38%	58.00%	65.98%	64.39%	53.06%	46.65%	35.46%	37.30%	20.06%
R&D to Revenue	331.33%	142.23%	60.42%	64.96%	83.87%	125.44%	100.39%	93.23%	71.08%	66.25%	26.31%
Operating Expenses to Revenue	554.58%	259.67%	130.72%	138.91%	174.61%	208.42%	163.52%	157.63%	146.86%	130.39%	49.91%
Earnings before Interest and Taxes (EBIT)	-168	-133	-66	-116	-227	-347	-432	-497	-429	-296	849
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-162	-128	-47	-89	-196	-260	-361	-364	-193	-232	871
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.91	3.13	4.42	4.94	4.98	8.64	1,958.20	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	4.91	3.13	29.52	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	30.20	4.53	3.56	6.54	9.64	10.94	5.23	3.93	2.22	4.32	3.52
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	8.93
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	11.19%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	5.86	6.00	11.67	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	23.48	2.91	3.32	6.26	8.43	8.85	4.59	4.16	1.59	3.26	2.57
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.10
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.23
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	5.23
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6.24
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	14.53	0.00	0.00	1.62	7.97	5.83
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.41	0.82	0.93	0.44	0.53	0.64	300.02	-1.65	-0.35	-0.26	-1.40
Long-Term Debt to Equity	0.41	0.82	0.93	0.40	0.49	0.64	196.03	-1.65	-0.35	-0.26	0.00
Financial Leverage	-1.07	-1.10	-0.65	-0.24	-0.47	-1.08	-2.35	0.52	0.37	0.75	1.93
Leverage Ratio	1.33	1.84	2.39	2.98	2.90	3.56	8.58	-10.54	-3.09	-1.88	-3.53
Compound Leverage Factor	1.35	1.95	2.84	3.30	3.06	4.14	10.28	-12.47	-5.01	-2.30	-2.90
Debt to Total Capital	28.90%	45.09%	48.10%	30.38%	34.56%	39.08%	99.67%	254.51%	-53.19%	-35.12%	352.48%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	2.32%	2.20%	0.00%	34.55%	0.00%	0.00%	0.00%	352.48%
Long-Term Debt to Total Capital	28.90%	45.09%	48.10%	28.06%	32.36%	39.08%	65.12%	254.51%	-53.19%	-35.12%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	71.10%	54.91%	51.90%	69.62%	65.44%	60.92%	0.33%	-154.51%	153.19%	135.12%	-252.48%
Debt to EBITDA	-0.57	-0.77	-3.09	-1.71	-1.60	-1.19	-1.20	-1.57	-1.47	-1.23	0.33
Net Debt to EBITDA	1.52	1.04	0.99	0.83	1.90	3.05	0.95	-0.44	3.07	3.69	-1.90
Long-Term Debt to EBITDA	-0.57	-0.77	-3.09	-1.58	-1.50	-1.19	-0.78	-1.57	-1.47	-1.23	0.00
Debt to NOPAT	-0.79	-1.06	-3.22	-1.89	-1.86	-1.02	-1.65	-1.83	-0.92	-1.35	0.34
Net Debt to NOPAT	2.11	1.44	1.03	0.92	2.21	2.63	1.30	-0.51	1.93	4.03	-1.95
Long-Term Debt to NOPAT	-0.79	-1.06	-3.22	-1.75	-1.74	-1.02	-1.08	-1.83	-0.92	-1.35	0.00
Altman Z-Score	2.12	-2.70	-0.69	0.24	0.83	0.59	-0.83	-1.73	-1.83	-1.80	1.85
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	7.84	5.27	3.04	1.92	3.30	4.44	1.87	1.71	2.02	2.35	2.35
Quick Ratio	7.71	5.17	2.82	0.76	3.15	4.23	1.74	1.39	1.72	2.23	2.20
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-113	-100	-169	-247	-114	232	-234	-468	917	329	761
Operating Cash Flow to CapEx	-4,571.21%	-5,831.42%	-324.51%	-389.47%	-717.01%	-1,087.66%	-890.84%	-1,113.99%	-557.06%	0.00%	8,090.97%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6.67	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-1.15	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-1.36	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.11	0.26	0.59	0.35	0.22	0.20	0.26	0.38	0.52	0.45	0.75
Accounts Receivable Turnover	4.73	4.59	5.95	4.89	4.97	6.07	5.97	5.25	5.93	5.05	10.18
Inventory Turnover	0.00	0.00	0.00	0.94	0.69	1.00	1.87	2.37	0.00	2.13	0.00
Fixed Asset Turnover	4.06	10.08	24.60	25.13	17.93	13.75	12.47	11.17	11.75	10.90	29.75
Accounts Payable Turnover	0.00	0.00	0.07	0.12	0.08	0.09	0.12	0.15	0.00	0.16	0.00
Days Sales Outstanding (DSO)	77.13	79.49	61.33	74.66	73.39	60.14	61.12	69.49	61.58	72.25	35.87
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	387.05	532.42	365.94	195.06	153.85	0.00	170.97	0.00
Days Payable Outstanding (DPO)	0.00	0.00	4,992.33	2,947.73	4,323.38	3,867.78	2,997.36	2,488.25	0.00	2,213.84	0.00
Cash Conversion Cycle (CCC)	77.13	79.49	-4,931.01	-2,486.02	-3,717.57	-3,441.70	-2,741.18	-2,264.91	61.58	-1,970.63	35.87
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-21	-14	110	276	222	-313	-341	-186	-1,411	-1,952	-1,864
Invested Capital Turnover	-1.94	-4.73	4.04	1.37	1.23	-8.38	-1.65	-2.65	-1.17	-0.48	-0.91
Increase / (Decrease) in Invested Capital	-4.30	7.21	124	166	-55	-534	-28	154	-1,225	-541	88
Enterprise Value (EV)	863	241	646	1,657	2,587	3,370	2,474	2,905	1,487	2,627	4,440
Market Capitalization	1,110	374	692	1,732	2,960	4,164	2,816	2,744	2,080	3,481	6,099
Book Value per Share	$6.59	$3.48	$3.77	$6.95	$9.64	$7.06	$0.02	($4.83)	($10.85)	($14.24)	($2.56)
Tangible Book Value per Share	$6.59	$3.48	$0.57	($8.57)	($3.22)	($4.63)	($11.40)	($15.79)	($16.97)	($16.85)	($8.42)
Total Capital	318	218	301	504	908	791	433	225	-534	-813	81
Total Debt	92	98	145	153	314	309	431	572	284	285	287
Total Long-Term Debt	92	98	145	141	294	309	282	572	284	285	0.00
Net Debt	-247	-133	-46	-75	-373	-795	-342	161	-593	-854	-1,659
Capital Expenditures (CapEx)	2.72	1.78	3.10	7.10	14	18	28	32	28	-22	8.79
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-28	-20	-24	-62	-123	-149	-179	-123	-261	-355	-353
Debt-free Net Working Capital (DFNWC)	311	212	167	166	563	954	595	288	616	785	1,592
Net Working Capital (NWC)	311	212	167	154	543	954	445	288	616	785	1,306
Net Nonoperating Expense (NNE)	53	50	34	47	83	136	262	246	319	151	167
Net Nonoperating Obligations (NNO)	-247	-133	-46	-75	-373	-795	-342	161	-593	-854	-1,659
Total Depreciation and Amortization (D&A)	5.46	5.48	19	26	31	86	71	132	236	64	22
Debt-free, Cash-free Net Working Capital to Revenue	-77.14%	-24.19%	-12.47%	-23.37%	-40.11%	-39.19%	-33.20%	-17.62%	-27.85%	-44.02%	-20.41%
Debt-free Net Working Capital to Revenue	844.70%	255.92%	85.92%	62.60%	183.54%	250.66%	110.39%	41.15%	65.63%	97.24%	92.00%
Net Working Capital to Revenue	844.70%	255.92%	85.92%	58.19%	177.02%	250.66%	82.63%	41.15%	65.63%	97.24%	75.44%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($5.07)	($4.17)	($2.02)	($2.75)	($4.27)	($6.64)	($7.43)	($7.79)	($8.37)	($4.73)	$8.58
Adjusted Weighted Average Basic Shares Outstanding	34.27M	34.56M	41.80M	58.40M	62.63M	70.32M	70.47M	71.73M	74.84M	76.85M	79.53M
Adjusted Diluted Earnings per Share	($5.07)	($4.17)	($2.02)	($2.75)	($4.27)	($6.64)	($7.43)	($7.79)	($8.37)	($4.73)	$7.78
Adjusted Weighted Average Diluted Shares Outstanding	34.27M	34.56M	41.80M	58.40M	62.63M	70.32M	70.47M	71.73M	74.84M	76.85M	88.31M
Adjusted Basic & Diluted Earnings per Share	($5.07)	($4.17)	($2.02)	($2.75)	($4.27)	($6.64)	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	33.63M	34.04M	39.18M	46.58M	58.86M	66.03M	71.36M	73.82M	76.61M	78.87M	82.77M
Normalized Net Operating Profit after Tax (NOPAT)	-117	-92	-45	-81	-169	-302	-262	-290	-155	-100	840
Normalized NOPAT Margin	-318.20%	-111.77%	-23.15%	-30.59%	-54.99%	-79.38%	-48.67%	-41.47%	-16.55%	-12.34%	48.54%
Pre Tax Income Margin	-462.28%	-171.14%	-39.95%	-48.39%	-78.16%	-105.82%	-96.24%	-84.07%	-74.23%	-45.01%	40.25%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-3.12	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-2.24	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-3.33	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-2.44	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from PTC Therapeutics' official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	82,774,730.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	82,774,730.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-0.03
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-9.47%	83.41%	-4.66%	-12.68%	0.11%	-30.58%	459.73%	-4.19%	7.23%	-22.75%	-76.83%
EBITDA Growth	-6.44%	182.40%	112.61%	75.57%	30.68%	-243.77%	11,817.45%	2.25%	128.22%	49.19%	-94.00%
EBIT Growth	-30.19%	115.00%	59.26%	79.70%	59.27%	-719.58%	2,297.62%	3.67%	116.88%	45.36%	-95.17%
NOPAT Growth	-73.29%	102.91%	61.35%	80.81%	53.87%	-2,890.19%	2,941.90%	13.08%	105.53%	56.06%	-96.52%
Net Income Growth	-21.64%	8.83%	34.10%	50.13%	19.79%	57.71%	1,046.28%	34.61%	114.90%	-104.85%	-100.32%
EPS Growth	-15.03%	11.91%	36.17%	51.50%	21.02%	58.94%	936.67%	35.66%	114.39%	-91.76%	-100.30%
Operating Cash Flow Growth	61.84%	39.57%	339.94%	-406.04%	-430.28%	70.08%	1,129.64%	18.36%	13.89%	-14.23%	-106.79%
Free Cash Flow Firm Growth	152.41%	517.10%	921.87%	2,562.21%	1,652.56%	-65.21%	3.61%	-93.18%	-116.51%	-132.33%	-108.21%
Invested Capital Growth	-68.73%	-658.36%	-769.88%	-419.10%	-354.23%	-38.36%	-28.98%	-6.77%	12.64%	4.52%	7.33%
Revenue Q/Q Growth	-8.06%	56.20%	-31.57%	-11.14%	5.40%	8.33%	451.71%	-84.79%	17.96%	-21.96%	65.51%
EBITDA Q/Q Growth	51.56%	236.77%	-92.16%	-570.07%	-37.47%	-183.63%	750.20%	-103.86%	139.69%	-610.69%	176.82%
EBIT Q/Q Growth	33.47%	117.90%	-277.00%	3.69%	-33.47%	-172.32%	727.80%	-104.22%	123.39%	-981.44%	155.51%
NOPAT Q/Q Growth	43.61%	104.93%	-880.98%	11.52%	-35.54%	-197.91%	895.45%	-102.71%	108.63%	-2,465.68%	163.01%
Net Income Q/Q Growth	33.14%	-17.16%	41.22%	-8.30%	-7.54%	38.22%	1,415.24%	-107.48%	124.51%	-949.05%	97.92%
EPS Q/Q Growth	33.83%	-17.61%	42.03%	-7.50%	-7.75%	38.85%	1,281.18%	-108.27%	124.10%	-915.00%	98.16%
Operating Cash Flow Q/Q Growth	-2.83%	-590.74%	170.56%	-200.98%	-7.75%	61.03%	2,999.96%	-106.70%	-13.66%	48.31%	-72.27%
Free Cash Flow Firm Q/Q Growth	234.15%	1,493.23%	5.01%	9.71%	-4.52%	-68.37%	212.73%	-92.78%	-331.22%	38.07%	20.60%
Invested Capital Q/Q Growth	-13.90%	-259.56%	-5.89%	-19.71%	0.34%	-9.52%	1.29%	0.91%	18.45%	-19.70%	4.19%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	95.17%	111.84%	100.00%	100.00%	100.00%	73.07%	98.91%	93.62%	100.00%	114.75%	89.72%
EBITDA Margin	-38.56%	33.76%	3.87%	-20.47%	-26.70%	-69.92%	82.40%	-20.89%	7.03%	-45.99%	21.34%
Operating Margin	-60.11%	1.90%	-21.63%	-21.54%	-27.70%	-76.18%	82.50%	-19.54%	1.43%	-43.33%	16.50%
EBIT Margin	-70.42%	8.07%	-20.87%	-22.63%	-28.65%	-72.03%	81.96%	-22.75%	4.51%	-50.95%	17.09%
Profit (Net Income) Margin	-67.64%	-50.74%	-43.58%	-53.12%	-54.20%	-30.91%	73.68%	-36.25%	7.53%	-81.96%	-1.03%
Tax Burden Percent	79.82%	99.20%	108.12%	115.68%	108.84%	69.57%	93.20%	91.27%	-68.89%	97.04%	114.09%
Interest Burden Percent	120.34%	-633.76%	193.10%	202.95%	173.80%	61.68%	96.46%	174.60%	-242.42%	165.78%	-5.29%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	6.80%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	142.96%	107.51%	85.72%	61.50%	52.54%	37.91%	-110.19%	-106.04%	-124.24%	-104.75%	101.97%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-39.64%	4.20%	-11.40%	-12.52%	-16.64%	-32.28%	65.37%	-17.65%	3.58%	-38.30%	5.12%
Return on Assets (ROA)	-38.07%	-26.43%	-23.79%	-29.40%	-31.47%	-13.85%	58.77%	-28.12%	5.98%	-61.62%	-0.31%
Return on Common Equity (ROCE)	142.96%	107.51%	85.72%	61.50%	52.54%	37.91%	-110.19%	-106.04%	-124.24%	-104.75%	101.97%
Return on Equity Simple (ROE_SIMPLE)	95.66%	0.00%	64.80%	48.92%	42.98%	0.00%	-320.22%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-83	4.07	-32	-28	-38	-114	904	-24	2.11	-50	31
NOPAT Margin	-42.08%	1.33%	-15.14%	-15.08%	-19.39%	-53.32%	76.88%	-13.68%	1.00%	-30.33%	11.55%
Net Nonoperating Expense Percent (NNEP)	36.86%	-74.10%	-38.00%	-24.76%	-30.45%	6.61%	-3.22%	-3.22%	1.29%	-6.77%	-2.05%
Return On Investment Capital (ROIC_SIMPLE)	-	-0.76%	-	-	-	13.99%	904.64%	-30.79%	1.62%	-61.42%	29.56%
Cost of Revenue to Revenue	4.83%	-11.84%	0.00%	0.00%	0.00%	26.93%	1.09%	6.38%	0.00%	-14.75%	10.28%
SG&A Expenses to Revenue	41.15%	24.85%	34.87%	37.22%	37.33%	39.73%	6.88%	47.67%	39.83%	58.83%	31.62%
R&D to Revenue	83.54%	39.52%	55.27%	70.79%	82.02%	58.53%	9.27%	63.17%	47.47%	80.84%	37.01%
Operating Expenses to Revenue	155.28%	109.95%	121.63%	121.54%	127.70%	149.25%	16.41%	113.16%	98.57%	158.07%	73.22%
Earnings before Interest and Taxes (EBIT)	-138	25	-44	-42	-56	-154	964	-41	9.52	-84	47
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-76	104	8.13	-38	-53	-149	969	-37	15	-76	58
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	2.12	2.22	2.40	2.60	3.17	4.32	2.27	2.19	2.74	3.52	6.82
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	6.76	6.15	6.49	8.93	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	14.80%	16.25%	15.42%	11.19%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	2.46	1.59	1.76	1.71	2.36	3.26	1.28	1.23	1.95	2.57	4.88
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	101.08	0.00	3.12	2.97	4.36	5.10	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	3.20	3.04	4.46	5.23	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	3.50	3.19	4.41	5.23	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	3.29	3.08	4.86	6.24	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	1.62	1.53	1.18	1.64	7.97	2.10	2.71	6.18	5.83	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	-0.85	-0.35	-0.32	-0.29	-0.27	-0.26	-1.54	-1.38	-1.84	-1.40	-1.59
Long-Term Debt to Equity	-0.85	-0.35	-0.32	-0.29	-0.27	-0.26	-1.54	-1.38	0.00	0.00	0.00
Financial Leverage	-0.30	0.37	0.23	0.37	0.26	0.75	2.17	2.12	1.76	1.93	9.14
Leverage Ratio	-3.16	-3.09	-2.51	-2.09	-1.80	-1.88	-4.12	-3.83	-3.71	-3.53	-15.09
Compound Leverage Factor	-3.80	19.58	-4.86	-4.24	-3.13	-1.16	-3.97	-6.70	8.99	-5.86	0.80
Debt to Total Capital	-587.05%	-53.19%	-46.69%	-40.96%	-37.06%	-35.12%	285.85%	359.91%	219.30%	352.48%	269.50%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	219.30%	352.48%	269.50%
Long-Term Debt to Total Capital	-587.05%	-53.19%	-46.69%	-40.96%	-37.06%	-35.12%	285.85%	359.91%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	687.05%	153.19%	146.69%	140.96%	137.06%	135.12%	-185.85%	-259.91%	-119.30%	-252.48%	-169.50%
Debt to EBITDA	-1.36	-1.47	-2.36	-128.12	13.56	-1.23	0.39	0.39	0.36	0.33	-7.16
Net Debt to EBITDA	-0.66	3.07	4.98	363.69	-34.63	3.69	-2.39	-2.33	-1.76	-1.90	40.04
Long-Term Debt to EBITDA	-1.36	-1.47	-2.36	-128.12	13.56	-1.23	0.39	0.39	0.00	0.00	0.00
Debt to NOPAT	-1.27	-0.92	-1.11	-2.05	-3.03	-1.35	0.44	0.42	0.36	0.34	-7.03
Net Debt to NOPAT	-0.62	1.93	2.33	5.83	7.74	4.03	-2.67	-2.51	-1.78	-1.95	39.32
Long-Term Debt to NOPAT	-1.27	-0.92	-1.11	-2.05	-3.03	-1.35	0.44	0.42	0.00	0.00	0.00
Altman Z-Score	-2.63	-1.04	-1.31	-1.19	-1.31	-1.52	2.03	0.67	0.75	0.79	0.56
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.10	2.02	2.03	2.23	2.10	2.35	3.89	3.62	2.32	2.35	2.44
Quick Ratio	0.94	1.72	1.88	2.10	1.99	2.23	3.76	3.48	2.18	2.20	2.29
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	77	1,229	1,291	1,416	1,352	428	1,337	97	-223	-138	-110
Operating Cash Flow to CapEx	-228.39%	-1,801.80%	738.02%	0.00%	-15,276.19%	-796.50%	52,605.99%	-4,429.23%	-1,924.56%	-1,443.68%	-4,932.50%
Free Cash Flow to Firm to Interest Expense	0.00	8.94	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	-0.73	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	-0.77	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.56	0.52	0.55	0.55	0.58	0.45	0.80	0.78	0.79	0.75	0.30
Accounts Receivable Turnover	5.50	5.93	4.64	4.94	4.93	5.05	8.69	9.21	8.83	10.18	3.84
Inventory Turnover	2.42	0.00	1.81	1.21	0.82	2.13	2.15	1.56	1.16	0.00	0.58
Fixed Asset Turnover	10.51	11.75	10.77	12.16	12.15	10.90	23.29	28.66	29.62	29.75	14.74
Accounts Payable Turnover	0.18	0.00	0.15	0.11	0.08	0.16	0.17	0.15	0.16	0.00	0.09
Days Sales Outstanding (DSO)	66.35	61.58	78.61	73.91	74.10	72.25	42.02	39.63	41.34	35.87	94.97
Days Inventory Outstanding (DIO)	150.61	0.00	201.57	301.77	447.65	170.97	170.05	233.88	313.65	0.00	633.18
Days Payable Outstanding (DPO)	2,085.12	0.00	2,356.75	3,296.17	4,431.68	2,213.84	2,132.45	2,405.78	2,269.98	0.00	4,107.73
Cash Conversion Cycle (CCC)	-1,868.17	61.58	-2,076.57	-2,920.50	-3,909.93	-1,970.63	-1,920.38	-2,132.27	-1,914.99	35.87	-3,379.58
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-392	-1,411	-1,494	-1,789	-1,783	-1,952	-1,927	-1,910	-1,557	-1,864	-1,786
Invested Capital Turnover	-2.55	-1.17	-1.11	-0.84	-0.83	-0.48	-1.04	-0.95	-1.07	-0.91	-0.45
Increase / (Decrease) in Invested Capital	-160	-1,225	-1,322	-1,444	-1,390	-541	-433	-121	225	88	141
Enterprise Value (EV)	1,967	1,487	1,628	1,537	2,126	2,627	2,278	2,168	3,474	4,440	4,034
Market Capitalization	1,688	2,080	2,229	2,345	2,854	3,481	4,019	3,871	4,875	6,099	5,639
Book Value per Share	($8.90)	($10.85)	($11.67)	($12.78)	($13.71)	($14.24)	($2.36)	($2.61)	($1.96)	($2.56)	($2.18)
Tangible Book Value per Share	($15.61)	($16.97)	($17.05)	($18.15)	($19.07)	($16.85)	($4.90)	($5.46)	($7.99)	($8.42)	($7.77)
Total Capital	-98	-534	-609	-695	-769	-813	100	79	131	81	106
Total Debt	573	284	285	285	285	285	286	286	286	287	287
Total Long-Term Debt	573	284	285	285	285	285	286	286	0.00	0.00	0.00
Net Debt	278	-593	-600	-808	-728	-854	-1,741	-1,703	-1,401	-1,659	-1,606
Capital Expenditures (CapEx)	6.36	5.57	9.59	-7.38	0.50	3.77	1.65	1.32	3.45	2.37	1.20
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-247	-261	-291	-345	-343	-355	-306	-344	-260	-353	-275
Debt-free Net Working Capital (DFNWC)	48	616	594	748	671	785	1,721	1,645	1,428	1,592	1,617
Net Working Capital (NWC)	48	616	594	748	671	785	1,721	1,645	1,142	1,306	1,330
Net Nonoperating Expense (NNE)	50	160	60	71	68	-48	38	40	-14	85	34
Net Nonoperating Obligations (NNO)	278	-593	-600	-808	-728	-854	-1,741	-1,703	-1,401	-1,659	-1,606
Total Depreciation and Amortization (D&A)	63	79	52	4.02	3.83	4.49	5.21	3.33	5.31	8.17	12
Debt-free, Cash-free Net Working Capital to Revenue	-30.89%	-27.85%	-31.33%	-38.33%	-38.03%	-44.02%	-17.27%	-19.50%	-14.61%	-20.41%	-33.26%
Debt-free Net Working Capital to Revenue	6.04%	65.63%	64.06%	83.08%	74.48%	97.24%	97.08%	93.21%	80.26%	92.00%	195.54%
Net Working Capital to Revenue	6.04%	65.63%	64.06%	83.08%	74.48%	97.24%	97.08%	93.21%	64.16%	75.44%	160.85%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.76)	($2.07)	($1.20)	($1.29)	($1.39)	($0.85)	$11.09	($0.83)	$0.20	($1.88)	($0.03)
Adjusted Weighted Average Basic Shares Outstanding	75.38M	74.84M	76.50M	76.73M	76.93M	76.85M	78.12M	78.15M	78.47M	79.53M	82.52M
Adjusted Diluted Earnings per Share	($1.76)	($2.07)	($1.20)	($1.29)	($1.39)	($0.85)	$10.04	($0.83)	$0.20	($1.63)	($0.03)
Adjusted Weighted Average Diluted Shares Outstanding	75.38M	74.84M	76.50M	76.73M	76.93M	76.85M	86.39M	78.15M	87.12M	88.31M	82.52M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	75.46M	76.61M	76.70M	76.92M	77.13M	78.87M	79.26M	79.44M	80.29M	82.77M	8.29M
Normalized Net Operating Profit after Tax (NOPAT)	-83	4.07	-32	-27	-37	-114	904	-24	2.44	-57	32
Normalized NOPAT Margin	-42.08%	1.33%	-15.14%	-14.42%	-18.73%	-53.32%	76.89%	-13.64%	1.16%	-34.70%	11.79%
Pre Tax Income Margin	-84.75%	-51.15%	-40.31%	-45.92%	-49.80%	-44.42%	79.06%	-39.72%	-10.94%	-84.46%	-0.90%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.18	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.03	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.14	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	-0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

PTC Therapeutics (PTCT) has shown a mix of liquidity strength and ongoing earnings volatility across the latest quarters. Below are the most important points for retail investors to consider, grouping positives first, then neutral observations, and finally potential red flags based on the last four years of data provided.

Strong near-term liquidity in early 2025. Cash & equivalents were about $1.48 billion in Q1 2025, supporting ongoing operations and pipeline work.
No long-term debt in several recent quarters. Long-term debt was reported as $0 in Q2 2025 and Q3 2025, reducing leverage risk.
Occasional quarterly profitability in select periods. Net income (continuing operations) was positive in Q1 2025 (+$866.56M) and again in Q3 2025 (+$15.90M), indicating earnings upticks in some quarters.
Financing activity supported liquidity in Q4 2025. Net cash from financing activities was about +$302.50M, providing additional liquidity.
Investing activity boosted cash in Q4 2025. Sale/maturity of investments contributed roughly +$390.65M in cash inflows, helping the cash balance.
Revenue volatility with no clear sustained YoY growth. Q4 2025 revenue was about $164.68M, down from Q3 2025’s $211.01M, and generally fluctuates quarter to quarter.
R&D spend remains high as a pipeline-focused biotech. R&D expenses in several quarters (e.g., Q4 2025 at $133.13M) stay substantial relative to revenue, aligning with ongoing drug development costs.
Impairment activity is mixed but often modest. Impairment charges are infrequent and can appear as small charges or reversals (e.g., Q4 2025 impairment reversal of about $10.3M).
Persistent net losses in many quarters. For example, Q4 2025 shows a net loss of about -$134.97M, highlighting ongoing profitability challenges.
Balance sheet risk with liabilities vs. assets. As of mid-2025, total liabilities (~$2.80B) exceeded total assets (~$2.64B), indicating negative equity and solvency risk.

05/20/26 08:25 PM ETAI Generated. May Contain Errors.

PTC Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, PTC Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

PTC Therapeutics' net income appears to be on a downward trend, with a most recent value of $682.64 million in 2025, falling from -$170.45 million in 2015. The previous period was -$363.30 million in 2024. Check out PTC Therapeutics' forecast to explore projected trends and price targets.

PTC Therapeutics' total operating income in 2025 was $866.94 million, based on the following breakdown:

Total Gross Profit: $1.73 billion
Total Operating Expenses: $863.72 million

Over the last 10 years, PTC Therapeutics' total revenue changed from $36.77 million in 2015 to $1.73 billion in 2025, a change of 4,607.2%.

PTC Therapeutics' total liabilities were at $3.10 billion at the end of 2025, a 10.7% increase from 2024, and a 2,128.7% increase since 2015.

In the past 10 years, PTC Therapeutics' cash and equivalents has ranged from $0.00 in 2018 to $984.65 million in 2025, and is currently $984.65 million as of their latest financial filing in 2025.

Over the last 10 years, PTC Therapeutics' book value per share changed from 6.59 in 2015 to -2.56 in 2025, a change of -138.8%.

Related Companies

Financial statements for NASDAQ:PTCT last updated on 5/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PTC Therapeutics (PTCT) Financials

Financials Breakdown Chart

Key Financial Trends

PTC Therapeutics Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PTC Therapeutics (PTCT) Financials

Annual Income Statements for PTC Therapeutics

Quarterly Income Statements for PTC Therapeutics

Annual Cash Flow Statements for PTC Therapeutics

Quarterly Cash Flow Statements for PTC Therapeutics

Annual Balance Sheets for PTC Therapeutics

Quarterly Balance Sheets for PTC Therapeutics

Annual Metrics And Ratios for PTC Therapeutics

Quarterly Metrics And Ratios for PTC Therapeutics

Financials Breakdown Chart

Key Financial Trends

PTC Therapeutics Financials - Frequently Asked Questions

When does PTC Therapeutics' financial year end?

How has PTC Therapeutics' net income changed over the last 10 years?

What is PTC Therapeutics' operating income?

How has PTC Therapeutics' revenue changed over the last 10 years?

How much debt does PTC Therapeutics have?

How much cash does PTC Therapeutics have?

How has PTC Therapeutics' book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools